<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532792</url>
  </required_header>
  <id_info>
    <org_study_id>PLA101</org_study_id>
    <secondary_id>HHSSO100200700031C</secondary_id>
    <nct_id>NCT00532792</nct_id>
  </id_info>
  <brief_title>A/H5N1 Dose Ranging Study With Adjuvant Patch</brief_title>
  <official_title>A Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Administered With and Without an Adjuvant Patch in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercell USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Intercell USA, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, randomized, observer-blind, placebo-controlled clinical trial. A maximum&#xD;
      of 500 eligible subjects in 10 groups will be enrolled, randomized and vaccinated in this&#xD;
      study. Subjects will receive an intramuscular injection of either the influenza A/H5N1 (low,&#xD;
      medium or high dose) or placebo on Day 0 and Day 21 with or without a patch. This study will&#xD;
      be performed in two parts.&#xD;
&#xD;
      In Part 1, an initial safety evaluation will be performed in 100 randomized subjects. A&#xD;
      Safety Review Committee (SRC)will review all safety data, including laboratory values,&#xD;
      through the Day 7 visit, and compare those data against Stopping Criteria. If the treatments&#xD;
      are considered safe, Part 2 of the study will be initiated and a second vaccination will be&#xD;
      administered to subjects in Part 1 on Day 21.&#xD;
&#xD;
      In Part 2, the remaining 400 subjects will be randomized, treated, and will follow the same&#xD;
      visit structure and protocol-defined requirements as subjects in Part 1, without the&#xD;
      additional laboratory safety measurements. An SRC review will also be performed of all safety&#xD;
      data through the Day 28 visit for subjects participating in Part 1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Intramuscular A/H5N1 with and without the LT adjuvant patch</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstration of adjuvant effect and evaluation of immunogenicity</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Pandemic Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21</description>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21</description>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21</description>
    <arm_group_label>Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1</intervention_name>
    <description>High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21</description>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21</description>
    <arm_group_label>Group 10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult males or females 18-49 years of age (inclusive)&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Women who are not post-menopausal or surgically sterile must have a negative serum or&#xD;
             urine pregnancy test at screening and within 24 hours of each vaccination with&#xD;
             understanding (through Informed Consent process) to not become pregnant and to employ&#xD;
             an effective form of birth control for the duration of the study. Acceptable forms of&#xD;
             birth control are: abstinence, hormonal contraceptives (oral, injectable, implant,&#xD;
             patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide),&#xD;
             and IUD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory abnormalities [as determined by the Toxicity Grading Scale (grade 1 4)] at&#xD;
             laboratory screening&#xD;
&#xD;
          -  Abnormalities at physical examination [as determined by the Toxicity Grading Scale&#xD;
             (grade 1-4)]&#xD;
&#xD;
          -  Known allergies to any component of the vaccine&#xD;
&#xD;
          -  Known egg protein allergy&#xD;
&#xD;
          -  Known allergies to adhesives&#xD;
&#xD;
          -  Known disturbance of coagulation&#xD;
&#xD;
          -  Participated in research involving investigational product within 45 days before&#xD;
             planned date of first vaccination&#xD;
&#xD;
          -  Donated or received blood or blood products such as plasma within the past 45 days&#xD;
&#xD;
          -  Received any licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks&#xD;
             (for live vaccines) prior to planned date of first vaccination&#xD;
&#xD;
          -  Ever received investigational enterotoxigenic E. coli, LT, or LT (R192G) or NasalFlu,&#xD;
             Berna Biotech, Ltd&#xD;
&#xD;
          -  Ever received cholera toxin or vaccine (e.g. Orochol™, Dukoral™)&#xD;
&#xD;
          -  History of travelers' diarrhea in the last two years&#xD;
&#xD;
          -  History of abdominal surgery (excluding C-section, hysterectomy, cosmetic surgery,&#xD;
             liposuction, appendectomy, cholecystectomy, ventral hernia repair, and other surgeries&#xD;
             not pertaining to gastrointestinal problems) or history of, or recent acute&#xD;
             gastrointestinal illness&#xD;
&#xD;
          -  Previous vaccination with a pandemic candidate vaccine or previous proven contact with&#xD;
             A/H5N1 wild type virus (contact with an individual with laboratory-confirmed A/H5N1&#xD;
             infection or contact with an animal which died as a result of A/H5N1 infection)&#xD;
&#xD;
          -  Recent or regular use of oral, topical or injected steroid medications within 45 days&#xD;
             prior to first vaccination&#xD;
&#xD;
          -  Use of immunosuppressive systemic steroid medications including inhaled steroids&#xD;
             within three months prior to first vaccination&#xD;
&#xD;
          -  Comorbid conditions or treatments that are immunosuppressive, including cancer,&#xD;
             diabetes, end-stage renal disease, as determined by the Investigator&#xD;
&#xD;
          -  Positive serology for HIV-1, HIV-2, HBsAg, or HCV&#xD;
&#xD;
          -  History of severe atopy&#xD;
&#xD;
          -  Medical history of acute or chronic skin disease at vaccination area(s)&#xD;
&#xD;
          -  Active skin allergy&#xD;
&#xD;
          -  Signs of acute skin infection, sunburn or skin abnormalities at the vaccination&#xD;
             area(s) including fungal infections, severe acne, or active contact dermatitis, or a&#xD;
             history of keloid formation&#xD;
&#xD;
          -  Hirsute (significant amount of hair) at vaccination area(s)&#xD;
&#xD;
          -  Artificial tanning (UV radiation) over the duration of the study including the&#xD;
             screening period&#xD;
&#xD;
          -  Visible tattoos or marks (tattoos/scars) at the vaccination area(s) that would prevent&#xD;
             appropriate dermatologic monitoring of the vaccination site(s)&#xD;
&#xD;
          -  Fever greater than or equal to 38.0°C (100.4°F) at the time of planned vaccination&#xD;
&#xD;
          -  Suspicion of or recent history of (within one year of planned vaccination) alcohol or&#xD;
             substance abuse&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Acute illness at screening or at baseline&#xD;
&#xD;
          -  Ever had a serious reaction to prior influenza vaccination&#xD;
&#xD;
          -  Developed a neurological disorder (such as Guillain Barré syndrome) in the six weeks&#xD;
             following a previous influenza vaccination&#xD;
&#xD;
          -  Medical history of achlorhydria&#xD;
&#xD;
          -  Employee of the investigational site&#xD;
&#xD;
          -  History of employment in bird or poultry industries or considerable exposure to birds&#xD;
             (e.g. poultry or bird veterinarians, bird breeders, poultry butchers and/or cullers,&#xD;
             etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Leese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Phase One Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Solano Clinical Research</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quintiles Phase One Services</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Kinetics</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avian</keyword>
  <keyword>Pandemic</keyword>
  <keyword>Influenza</keyword>
  <keyword>A/H5N1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

